TELA Bio, Inc.·4

Nov 13, 8:48 PM ET

Friedman Ashley 4

4 · TELA Bio, Inc. · Filed Nov 13, 2019

Insider Transaction Report

Form 4
Period: 2019-11-13
Transactions
  • Conversion

    Warrant (right to buy)

    2019-11-13+31,16831,168 total(indirect: By Partnership)
    Exercise: $28.65From: 2019-11-13Exp: 2027-01-18Common Stock (1,262 underlying)
  • Conversion

    Warrant (right to buy)

    2019-11-13+148,499148,499 total(indirect: By Partnership)
    Exercise: $28.65From: 2019-11-13Exp: 2027-01-18Common Stock (6,014 underlying)
  • Conversion

    Series B Preferred Stock

    2019-11-137,051,0090 total(indirect: By Partnership)
    Common Stock (285,580 underlying)
  • Conversion

    Common Stock

    2019-11-13+59,940106,052 total(indirect: By Partnership)
  • Conversion

    Common Stock

    2019-11-13+285,580505,281 total(indirect: By Partnership)
  • Conversion

    Warrant (right to buy)

    2019-11-1331,1680 total(indirect: By Partnership)
    Exercise: $1.16From: 2017-01-18Exp: 2027-01-18Series B Preferred Stock (31,168 underlying)
  • Conversion

    Series B Preferred Stock

    2019-11-131,479,9510 total(indirect: By Partnership)
    Common Stock (59,940 underlying)
  • Conversion

    Warrant (right to buy)

    2019-11-13148,4990 total(indirect: By Partnership)
    Exercise: $1.16From: 2017-01-18Exp: 2027-01-18Series B Preferred Stock (148,499 underlying)
Footnotes (5)
  • [F1]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
  • [F2]Reflects 46,112 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
  • [F3]Reflects 219,701 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
  • [F4]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
  • [F5]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT